Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 Study - PubMed
5 hours ago
- #Pembrolizumab
- #Immunotherapy
- #Hepatocellular Carcinoma
- Pembrolizumab monotherapy was evaluated in sorafenib-treated (cohort 1) and treatment-naive (cohort 2) advanced HCC patients in the KEYNOTE-224 study.
- Median follow-up was ~7 years for cohort 1 and ~5 years for cohort 2.
- Median overall survival (OS) was 13.2 months for cohort 1 and 16.9 months for cohort 2.
- 24/48-month OS rates were 31%/17% for cohort 1 and 34%/20% for cohort 2.
- Median progression-free survival (PFS) was 4.9 months for cohort 1 and 4.3 months for cohort 2.
- Treatment-related adverse events occurred in 73.1% of cohort 1 (26.0% grade 3-5) and 54.9% of cohort 2 (15.7% grade 3-5).
- Pembrolizumab demonstrated durable response and manageable safety, with long-term OS effects beyond 48 months in some patients.